BAINBRIDGE ISLAND, WA, A leading protein science solutions company today

announced strategic changes including new leadership and a new company name. Emerald BioSystems,

known for its protein purification instruments and esteemed Wizard line of protein crystallography

applications, will now be known as Emerald Bio. The new management changes include the appointment

of CEO, George Abe, and the promotion of Dr. Peter Nollert to Chief Technologist. These changes are part

of the strategy to address the fact that protein scientists are facing more difficult proteomics targets in

larger numbers, problems Emerald Bio has already solved while enabling structural genomics and drug

discovery initiatives.

“Our new company name, as well as our personnel changes, reflect Emerald’s strengthening position in the

protein science industry and our renewed dedication to meeting our customers’ growing demands,” said

Johan Pontin, Chairman of the Board of Beryllium, LLC, which owns Emerald Bio and its sister company,

Emerald BioStructures.

“These changes will help Emerald Bio better address the growing demand for high performance and high

quality protein science solutions,” said George Abe, CEO of Emerald Bio and veteran in the

commercialization of biotechnology. “Emerald Bio’s protein technology expertise provides high quality

reagents, instruments, and consumables—products that are making key contributions to the growing field

of proteomics.”

Peter Nollert, Emerald Bio’s Chief Technologist and renowned membrane protein scientist commented,

“Our strategic vision is to create technology solutions that respond to trends in the growing proteomics

field. Emerald Bio’s historical leadership in protein crystallography puts us in a strong position to serve all

scientists who work in protein science.”

George Abe is known for leading companies, and building teams, focused on applying innovation to

address critical unmet needs in life sciences. He was most recently CEO of Cambridge Research and

Instrumentation (CRi), a provider of multiplexed biomarker imaging solutions. CRi was acquired by Caliper

Life Sciences (now Perkin Elmer), where he held the position of Senior Vice President, Tissue Imaging. He

has also held senior positions at several high technology organizations, including technology pioneer, BBN.

He has also served on the board of directors of several public and private medical device and technology

companies. George earned a B.S. degree from Trinity College, a M.S. degree from the University of

Connecticut, and is a graduate of the Greater Boston Executive Program at the Sloan School of

Management, MIT.

Peter Nollert is a recognized expert in structural and membrane protein science. He earned a PhD in

Biochemistry at the University of Tuebingen, and Post-doctorate fellowships at University of Basel,

Stanford, and UCSF. Peter holds five U.S. patents, has published more than 30 articles in peer-reviewed

journals, and obtained several NIH-funded grants for membrane protein crystallization and imaging

technology development.

Company Information:

Emerald Bio is a leading provider of protein science solutions. We develop and supply sophisticated

laboratory automation systems, reagent kits, stock solutions, proteins, and accessories for proteinresearchers. An innovation leader, the team at Emerald Bio continues to create award-winning research

tools that accelerate discovery and decision-making in protein labs worldwide. Our instrument solutions

automate protein purification, liquid handling, and protein crystallization. Our Wizard Line of reagents and

our stock solutions are available individually, in convenient screens, and as custom products. As the 7869 NE Day Road West • Bainbridge Island, WA USA 98110 • Main Office: 1-888-780-8588 • Fax: 1-206-780-8929

demands of protein research continue to grow, we also provide high purity proteins. For more information,

please visit www.emeraldbiosystems.com or call 1-888-780-8588.

Corporate Information:

The Emerald companies (Emerald Bio and Emerald BioStructures) are wholly owned by Beryllium LLC, a

Delaware Limited Liability Company, and are financed by a group of strong investors, including: Arctaris,

Eastern Growth Captial, Gemini Investors, and Kendall Square Partners.